Form 4: Kiniksa Pharmaceuticals Executive Ross Moat Reports Stock Transactions

Chief Commercial Officer Ross Moat reports acquisition and disposal of Kiniksa Pharmaceuticals shares and derivative securities.

Summary

• Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals, reported transactions involving the company's stock.
• On April 8, 2024, Moat acquired 2,477 Class A Common Shares and disposed of 1,353 shares to cover tax obligations at a price of $17.9 per share.
• Following these transactions, Moat directly owns 16,276 Class A Common Shares.
• Moat was also granted 36,100 share options, 5,569 performance share units (PSUs), and 6,962 restricted share units (RSUs) on April 4, 2024.
• Moat directly owns 36,100 share options, 5,569 performance share units (PSUs), and 11,795 restricted share units (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document simply reports transactions by an insider, which is a normal part of corporate governance. There is no indication of positive or negative performance.

Positives

• The granting of share options, PSUs, and RSUs to the Chief Commercial Officer aligns his interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the equity grants suggest a long-term commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the activity of a key executive in Kiniksa Pharmaceuticals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly altering the ownership structure.

Key Dates